CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-06-01 | Ehlers Michael D EVP, Research and Development | Grant or award · Restricted Stock Unit | +7,320 | 7,320 | ||
| 2016-06-01 | SCANGOS GEORGE A Chief Executive Officer | Sale | −487 | $287.97 | $140K | 55,778 |
| 2016-05-31 | SCANGOS GEORGE A Chief Executive Officer | Sale | −3,368 | $290.00 | $977K | 56,265 |
| 2016-05-25 | SCANGOS GEORGE A Chief Executive Officer | Sale | −157 | $280.00 | $44K | 59,633 |
| 2016-05-02 | Vounatsos Michel EVP & Chief Commercial Officer | Grant or award · Restricted Stock Unit | +9,520 | 9,520 | ||
| 2016-05-02 | SCANGOS GEORGE A Chief Executive Officer | Sale | −487 | $274.74 | $134K | 59,790 |
| 2016-05-01 | COVINO GREGORY F VP, Chief Accounting Officer | Exercise or conversion | +348 | 3,119.82 | ||
| 2016-05-01 | COVINO GREGORY F VP, Chief Accounting Officer | Shares withheld for taxes | −113 | $274.99 | $31K | 3,006.82 |
| 2016-05-01 | COVINO GREGORY F VP, Chief Accounting Officer | Exercise or conversion · Restricted Stock Unit | −348 | 0 | ||
| 2016-04-06 | Koppel Adam EVP, Strategy and Bus. Dev. | Sale | −102 | $275.00 | $28K | 1,848.11 |
| 2016-04-06 | SCANGOS GEORGE A Chief Executive Officer | Sale | −157 | $280.00 | $44K | 60,277 |
| 2016-04-02 | Artavanis-Tsakonas Spyridon EVP, Chief Scientific Officer | Exercise or conversion | +975 | 3,608.97 | ||
| 2016-04-02 | Artavanis-Tsakonas Spyridon EVP, Chief Scientific Officer | Shares withheld for taxes | −459 | $260.54 | $120K | 3,149.97 |
| 2016-04-02 | Artavanis-Tsakonas Spyridon EVP, Chief Scientific Officer | Exercise or conversion · Restricted Stock Unit | −975 | 0 | ||
| 2016-04-01 | Cox John EVP Pharmaceutical Oper & Tech | Grant or award | +8,444 | 39,045.24 | ||
| 2016-04-01 | SCANGOS GEORGE A Chief Executive Officer | Sale | −487 | $258.83 | $126K | 60,434 |
| 2016-03-01 | SCANGOS GEORGE A Chief Executive Officer | Sale | −487 | $261.37 | $127K | 60,921 |
| 2016-02-25 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Sale | −183 | $261.90 | $48K | 7,990 |
| 2016-02-25 | Karaboutis Adriana EVP, Tech, Bus. Sol & Corp Aff | Sale | −84 | $261.90 | $22K | 8,127 |
| 2016-02-23 | Clancy Paul J Executive VP and CFO | Exercise or conversion | +579 | 27,143 |
Page 70 of 73 · 1,456 trades